SSY Group Limited disclosed that Mr. Wu Hengyao, aged 57, will become an executive director effective 28 September 2026. Concurrently, Mr. Su Xuejun will resign from the same position on the stated date to concentrate on other professional commitments.
Mr. Wu is currently a director of New Orient Investments Pharmaceutical Holding (Hong Kong) Limited and Shijiazhuang No. 4 Pharmaceutical Co., Ltd., both wholly owned by SSY Group, and serves as president of Shijiazhuang No. 4. His background includes more than two decades in pharmaceutical sales and business management, supported by a Master’s degree in Business Administration from Tianjin University of Finance and Economics and a Senior Engineer qualification in the PRC.
Under a three-year service agreement, Mr. Wu will not receive a director’s fee but will earn a basic salary of HK$1.90 million per annum and may receive a discretionary bonus. His directorship remains subject to retirement by rotation and re-election at the company’s next annual general meeting.
SSY Group confirmed that Mr. Wu holds no shares in the company, maintains no relationships with existing directors or major shareholders, and has not served as a director of any other listed company in the past three years.
The board expressed its appreciation to Mr. Su for his contributions and extended a formal welcome to Mr. Wu. Following these changes, the board now comprises five executive directors, one non-executive director, and three independent non-executive directors.
Comments